Johnson & Johnson's anti-interleukin 23 candidate, guselkumab, has outperformed Abbvie Inc.'s Humira (adalimumab) in a second pivotal plaque psoriasis trial, firming up the foundation for potential U.S. and European regulatory approvals late this year.